Gastroenterology
Giuseppe Penna, from Humanitas University (Italy), presents the development of a novel postbiotic obtained from a single bacterial strain through an innovative fermentation process.
Giovanni Marasco, University of Bologna, discusses the growing evidence that links gut microbiota dysbiosis to the pathophysiology, clinical prognosis, disease progression, and treatment response of patients with IBD.
E. coli 541-15 helps the colon recruit key immune cells that can develop into macrophages.
A youthful gut microbiota can improve the regenerative function of aged intestinal stem cells.
VOS, an FDA-approved oral microbiota therapy, has been shown to reduce infection risk compared to traditional fecal transplants.
Effective treatment of IBD requires an approach combining tailored donors, microbiota analysis, and diet.
Gut Clostridia can be divided into two groups, with one group contributing to gut inflammation under certain conditions.
Maurizio Vecchi, gastroenterologist at Policlinico of Milan (Italy), discussed the current and potential role of the microbiome in inflammatory bowel disease (IBD).
Dietary protein influences V. cholerae growth, metabolism, virulence, and competition with gut microbes.
Industry, Gastroenterology
Sponsored by
How postbiotics are reshaping dietary supplements and pharma: key insights from Humiome® Post LB.
